rationale studies suggest patients asthma homozygous arginine 16th position receptor benefit betaagonists objectives investigated effects occur patients treated betaagonists effects modified concurrent inhaled corticosteroid ics use methods compared salmeterol response patients asthma homozygous arginine b16 homozygous glycine b16 separate cohorts subjects randomized regular therapy salmeterol simultaneously discontinuing ics therapy second subjects randomized regular therapy salmeterol continuing concomitant ics results trials subjects did benefit compared subjects salmeterol initiated cohort compared placebo addition salmeterol associated NUMBER lower peak expiratory flow pef p NUMBER subjectssalmeterol n NUMBER placebo n NUMBER compared subjects salmeterol n NUMBER placebo n NUMBER second cohort subjects treated salmeterol ics concurrently n NUMBER lower pef NUMBER difference p NUMBER subjects n NUMBER treated regimen addition b16 subjects second cohort lower fev1 NUMBER l p NUMBER increased symptom scores NUMBER units p NUMBER increased albuterol rescue use NUMBER p NUMBER compared subjects conclusions relative patients asthma patients asthma impaired therapeutic response salmeterol absence presence concurrent ics use investigation alternate treatment strategies benefit group beta2 adrenergic short acting genotype specific long acting b16arg arg b16gly gly b16arg arg b16gly gly l min b16arg arg b16gly gly b16arg arg l min b16gly gly arg arg puffs d b16gly gly b16gly gly b16arg arg